(Q44018770)

29 November 2017

1 reference

title

Pathogenetic and clinical aspects of C1 inhibitor deficiency (English)

1 reference

29 November 2017

M Cicardi

1

1 reference

29 November 2017

L Bergamaschini

2

1 reference

29 November 2017

M Cugno

3

1 reference

29 November 2017

A Beretta

4

1 reference

29 November 2017

L C Zingale

5

1 reference

29 November 2017

M Colombo

6

1 reference

29 November 2017

A Agostoni

7

1 reference

29 November 2017

publication date

1 August 1998

1 reference

29 November 2017

1 reference

29 November 2017

volume

199

1 reference

29 November 2017

issue

2

1 reference

29 November 2017

page(s)

366-376

1 reference

A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE.

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

C1 inhibitor hinge region mutations produce dysfunction by different mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

An IgG autoantibody which inactivates C1-inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Autoantibody-mediated acquired deficiency of C1 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angio-oedema

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Acquired angioedema and anti-C1-inhibitor autoantibody

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Autoimmune C1 inhibitor deficiency: Report of eight patients

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

An autoantibody to C1-inhibitor recognizes the reactive center of the inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Angioedema induced by a peptide derived from complement component C2.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

C1 inhibitor and hereditary angioneurotic edema

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: A rationale for prophylactic use of tranexamic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Thrombin's enzymatic activity increases permeability of endothelial cell monolayers

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Transmission of hepatitis G virus in patients with angioedema treated with steam-heated plasma concentrates of C1 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2898%2980041-7

7 January 2021

10.1016/S0171-2985(98)80041-7

Identifiers

DOI

0 references

1 reference